Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-561-1 | CAS number: 108-21-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Adequate studies of the repeated dose toxicity of isopropyl acetate were not found. The repeated dose toxicity of the in vivo hydrolysis product, isopropanol, has been studied by inhalation in rats and mice. The NOAEL of 500 ppm isopropanol seen in the rat and mouse corresponds to 394 ppm (1.675 mg/L) isopropyl acetate and a LOAEL of 1500 ppm isopropyl alcohol corresponds to 1181 ppm (4.9 mg/L) isopropyl acetate after correcting for differences in total respiratory bioavailability.
Exposure to high concentrations of isopropyl acetate or the in vivo hydrolysis product isopropanol have been reported to produce narcosis in exposed rats. No presistent neurotoxicity was seen in subchronic studies of isopropanol. Data on ethyl acetate can be used to predict the potential for local effects through hydrolysis in the URT. Based on this available data, the BMDL10 for isopropyl acetate is predicted to be in the region 272 -523mg/m3
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 1 650 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- BMCL10
- 272 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
There is no reliable repeat dose toxicity data available on isopropyl acetate. For the purposes of this end point, read across to the hydrolysis products isopropyl acetate and acetic acid (using ethyl acetate as a proxy) are used to predict systemic and local toxicity.
In a sub-chronic repeated dose inhalation study performed to a US national guideline, CD-1 mice were exposed to isopropanol vapour concentrations of 100, 500, 1500 and 5000ppm for a period of 90 days. No mortalities were seen. The narcotic effects of isopropanol were noted at the two higher exposures, producing ataxia, narcosis and a lack of startle reflex in some animals. These symptoms disappeared after exposure. Significant adverse effects were limited to the 5000ppm females, and included increased body weight and body weight gain, increased food consumption, changes to haematology and increased relative liver weight. A 10% increase in the latter was also noted in the 1500ppm females. Based on the clinical changes due to narcosis and the marginal liver weight changes seen at 1500ppm in females (which could be adaptive changes) a NOEL of 500ppm was established.
In a sub-chronic repeated dose inhalation study performed to a US national guideline, F-344 rats were exposed to isopropanol vapour concentrations of 100, 500, 1500 and 5000ppm for a period of 90 days (Burleigh-Flayer, 1994). No mortalities were seen. In addition, a satellite group of animals exposed to the three higher doses were subjected to functional observation battery (FOB) assessment. The two higher doses caused depressed central nervous system function (e.g. narcosis, hypoactivity) during exposure. Some adverse clinical signs persisted in the high dose animals. Exposure of female rats to 5000 ppm (12.25 mg/L) also increased motor activity during nine and 13 weeks of the study but no persistent neurotoxicity was noted in any dose groups. Increases in body weight and/or body weight gain were noted in the two highest dose groups. Changes in clinical pathology and relative liver weight changes were noted in the high dose animals. Hylaine droplets were seen within the kidneys of male rats, including controls. There did seem to be a trend towards increased severity, but this was not clearly concentration related. Such lesions are known to affect rats but not humans so their relevance to human risk assessment is highly questionable. The NOAEL in the 13-week rat study was determined to be 500 ppm (1.23 mg/L) based on decreases in red blood cell parameters in the male and female rats and the during-exposure clinical signs noted in the 1500 and 5000 ppm (3.68 and 12.23 mg/L) groups. In the FOB part of this study there were signs of narcosis in the first 2 weeks of exposure to isopropanol vapour at the top vapour concentration. Thereafter there was evidence of adaptation (tolerance) and in the absence of histological neuropathology the effects are not considered to be adverse. The NOAEL for neurotoxic effects by inhalation exposure is 5000 ppm.
In a guideline and GLP study, rats exposed to concentrations of 350, 750, or 1500 ppm (1.28, 2.75, 5.49 mg/L) of ethyl acetate in air for 94 days showed no significant toxic effects. Diminished response to delivery of an alerting stimuli was noted during exposure at the 750 and 1500 ppm levels. This transient diminished response was confined to the exposure period and was attributed to acute sedative properties of ethyl acetate. Other findings at the 750 and 1500 ppm levels were limited to reduced food consumption and body weight gain (both primarily in females at 750ppm), and lower levels of serum triglycerides. No other changes were seen. Some evidence of nasal mucosa degeneration was seen at 350 ppm.
The NOAEL for systemic toxicity in this study was considered to be 350 ppm (1.28 mg/L) and the LOAEL 750ppm (2.75 mg/L). The LOAEL for respiratory irritant effects (nasal toxicity) was considered to be 350 ppm (1.28 mg/L).
From
the results of these studies, it can be considered that local effects
are the critical effects rather than effects resulting from systemic
exposure. The
ethyl acetate study is therefore used to derive the critical parameter
for inhalation exposure.
Justification for classification or non-classification
Classification for repeat dose target organ effects become relevant when effects are seen at doses resulting from inhalation exposure of less than 250ppm. There is no evidence of possible systemic toxicity resulting from exposures at such concentrations – the NOAEL for isopropanol is 500ppm. For local effects, the only consideration is the nasal olfactory lesions for which a LOAEL of 350ppm is seen in the ethyl acetate study and for which a BMDL10 of 64-123ppm is calculated based on local tissue concentrations of the metabolite acetic acid. However, it should be noted that the lesions seen at this concentration in 60% of the animals were rated as only mild and, more importantly, that the predicted human equivalent concentration for such effects is at least 6x higher based on the same metric. Based on the source substances and considering the human relevance of the findings in animals, there is no evidence that isopropyl acetate would exhibits any specific repeat dose toxicity that would warrant classification according to the CLP criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.